Advertisement
Canada markets open in 8 hours 37 minutes

  • S&P/TSX

    22,011.72
    +139.76 (+0.64%)
     

  • S&P 500

    5,070.55
    +59.95 (+1.20%)
     

  • DOW

    38,503.69
    +263.71 (+0.69%)
     

  • CAD/USD

    0.7318
    -0.0002 (-0.03%)
     

  • CRUDE OIL

    83.44
    +0.08 (+0.10%)
     

  • Bitcoin CAD

    91,553.67
    +874.76 (+0.96%)
     

  • CMC Crypto 200

    1,436.50
    +21.74 (+1.54%)
     

  • GOLD FUTURES

    2,341.50
    -0.60 (-0.03%)
     

  • RUSSELL 2000

    2,002.64
    +35.17 (+1.79%)
     

  • 10-Yr Bond

    4.5980
    -0.0250 (-0.54%)
     

  • NASDAQ futures

    17,729.75
    +123.00 (+0.70%)
     

  • VOLATILITY

    15.69
    -1.25 (-7.38%)
     

  • FTSE

    8,044.81
    +20.94 (+0.26%)
     

  • NIKKEI 225

    38,382.18
    +830.02 (+2.21%)
     

  • CAD/EUR

    0.6833
    -0.0003 (-0.04%)
     

Plasma Continues to Drive Strong Growth for HAE in Fiscal 2018

Margaret Patrick
Updated
Plasma Continues to Drive Strong Growth for HAE in Fiscal 2018

In fiscal 3Q18, Haemonetics (HAE) reported revenue of close to $113.1 million, a YoY (year-over-year) rise of ~4.1%. Haemonetics has earned revenue of nearly $324.4 million from the sale of its products in the plasma franchise YTD (year-to-date) in fiscal 2018, which reflects a YoY rise of ~4.7%. The franchise has reported organic revenue growth of close to 6% YTD in fiscal 2018, and it’s expected to continue witnessing robust growth owing to solid demand for drugs based on human plasma.

Continue reading